Integra LifeSciences Corporation is presently staging the full market release of its Hollywood VI intervertebral body fusion device (IBD) system. According to Integra’s April 30 news release, the Hollywood VI IBD is used primarily in transforaminal lumbar interbody fusion (TLIF), a surgical procedure designed to help alleviate pain and nerve compression by fusing and stabilizing adjacent vertebrae in the lower back.
Integra Launches Hollywood Lower Back IBD System

The release states that the Hollywood VI IBD incorporates a variable insertion feature, which enables surgeons to choose the appropriate delivery angle for the implant and gives more flexibility in managing varying patient anatomy. It includes a new, longer, 30mm implant that increases the bone graft volume by 33% over the current 27mm implant, and provides a larger platform to help promote spinal fusion.
IBDs are designed to help provide stability for spinal fusion after a diseased disc is surgically removed. They are small, hollow spinal implants that are inserted into the intervertebral space to restore physiological disc height and allow fusion between vertebral bodies. The graft window in the device is packed with bone and provides an environment in which natural bone growth can occur, which then enables fusion of the vertebral segments.
“Integra has developed a TLIF cage that is simple to insert, due to the variable angle insertion mechanism, while maximizing fusion rates by aggressively increasing graft space within the cage, compared to its competitors, ” said Thomas N. Scioscia, M.D., OrthoVirginia, Richmond, Virginia.
“We are always looking for ways to better serve our surgeons, ” said Kirt Stephenson, Integra’s President, U.S. Spine. “Our new Hollywood VI IBD does just that, by providing our customers with additional solutions that help meet their patients’ needs.”

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.